63 related articles for article (PubMed ID: 37458509)
1. Age and clinical decision making in oncology patients.
Yellen SB; Cella DF; Leslie WT
J Natl Cancer Inst; 1994 Dec; 86(23):1766-70. PubMed ID: 7966414
[TBL] [Abstract][Full Text] [Related]
2. Marginal Gains and Clinical Trials - Improving and Influencing Practice.
Gilbert DC; Henry AM; Choudhury A
Clin Oncol (R Coll Radiol); 2022 Jul; 34(7):419-420. PubMed ID: 35491365
[No Abstract] [Full Text] [Related]
3. Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed.
Walia A; Tuia J; Prasad V
Nat Rev Clin Oncol; 2023 Dec; 20(12):885-895. PubMed ID: 37828154
[TBL] [Abstract][Full Text] [Related]
4. Patients' attitudes and preferences toward delayed disease progression in the absence of improved survival.
Brundage MD; Booth CM; Eisenhauer EA; Galica J; Kankesan J; Karim S; Koven R; McDonald V; Ng T; O'Donnell J; Ten Hove J; Robinson A
J Natl Cancer Inst; 2023 Dec; 115(12):1526-1534. PubMed ID: 37458509
[TBL] [Abstract][Full Text] [Related]
5. The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature.
Raphael MJ; Robinson A; Booth CM; O'Donnell J; Palmer M; Eisenhauer E; Brundage M
JAMA Oncol; 2019 Dec; 5(12):1779-1789. PubMed ID: 31556921
[TBL] [Abstract][Full Text] [Related]
6. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
[TBL] [Abstract][Full Text] [Related]
7. Patients' and oncologists' preferences for second-line maintenance PARP inhibitor therapy in epithelial ovarian cancer.
Stone RL; Cambron-Mellott MJ; Beusterien K; Maculaitis MC; Ritz S; Mulvihill E; Monberg M; Szamreta EA; Amin S; McLaurin K
Future Oncol; 2022 Feb; 18(4):491-503. PubMed ID: 34875854
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
9. Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.
Michaeli DT; Michaeli T
J Clin Oncol; 2022 Dec; 40(35):4095-4106. PubMed ID: 35921606
[TBL] [Abstract][Full Text] [Related]
10. Patient perspectives of value of delayed disease progression on imaging (imaging PFS). A treatment trade-off experiment.
Robinson AG; O'Donnell J; Booth C; Koven R; Eisenhauer E; Brundage M
J Cancer Policy; 2021 Dec; 30():100301. PubMed ID: 35559797
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
Del Paggio JC; Berry JS; Hopman WM; Eisenhauer EA; Prasad V; Gyawali B; Booth CM
JAMA Oncol; 2021 May; 7(5):728-734. PubMed ID: 33764385
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Patient Preferences in Lung Cancer - Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects.
Janssen EM; Dy SM; Meara AS; Kneuertz PJ; Presley CJ; Bridges JFP
Patient Prefer Adherence; 2020; 14():927-937. PubMed ID: 32581519
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
